Dry eye/OSD
Not All DED Patients Have Chronic Symptoms
By Richard A. Adler, MD, FACS; and Nathan M. Radcliffe, MD Specialists now have a topical medication specifically approved for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease (DED). With the availability of Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%; Kala Pharmaceuticals), we...
Read MoreStay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved